1992
DOI: 10.1002/hon.2900100108
|View full text |Cite
|
Sign up to set email alerts
|

Gastric cancer: Chemotherapy of advanced disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

1994
1994
2007
2007

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(7 citation statements)
references
References 15 publications
0
7
0
Order By: Relevance
“…Furthermore, given that many of the patients are diagnosed when the disease is unsuitable for curative surgery, there is a pressing need to develop better systemic therapies in adjuvant, neoadjuvant and metastatic settings (Macdonald et al, 1992).…”
mentioning
confidence: 99%
“…Furthermore, given that many of the patients are diagnosed when the disease is unsuitable for curative surgery, there is a pressing need to develop better systemic therapies in adjuvant, neoadjuvant and metastatic settings (Macdonald et al, 1992).…”
mentioning
confidence: 99%
“…1983; Machover et al . 1986; MacDonald 1992) and the synergistic activity of 5‐FU and cisplatin (Kim et al . 1993).…”
Section: Discussionmentioning
confidence: 99%
“…The choice of drugs in this trial was based on their single-agent activity in upper-gastrointestinal cancers (Beer et al 1983;Machover et al 1986;MacDonald 1992) and the synergistic activity of 5-FU and cisplatin (Kim et al 1993). We obtained a PR rate of 11.3% and 1-year OS rate of 11.32% with this regimen.…”
Section: Discussionmentioning
confidence: 99%
“…The degree of necrosis and its prognostic significance depend upon numerous factors and are classified according to the neoplastic histology and the specific anatomic substrate [13]. For example, chemotherapy-induced necrosis in neoadjuvant therapy of osteosarcomas must be superior to 90% of the lesion volume to be regarded as prognostically favorable, whereas in other neoplasms (gastric and breast carcinomas) lower ratios, always during neoadjuvant courses, may still constitute satisfactory results [27,28,29,30,31,32]. Local treatment of hepatocellular carcinomas represents one of the most extensively studied models for the definition of imaging parameters related to therapy-induced tumor necrosis [33,34,35,36].…”
Section: Necrosismentioning
confidence: 99%